<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417976</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-05110</org_study_id>
    <secondary_id>NCI-2011-03230</secondary_id>
    <nct_id>NCT00417976</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer</brief_title>
  <official_title>A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tony Bekaii-Saab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of biweekly (every other week) bevacizumab followed by gemcitabine
      then infusional 5-fluorouracil in patients with stage III or IV pancreatic cancer. Patients'
      response will be evaluated every 8 weeks using usual CT scanning techniques. RECIST
      (Response Evaluation Criteria in Solid tumors) criteria will be applied to evaluate
      response. Tumor marker levels (Ca 19-9) will be assessed every 4 weeks, but will not be used
      to measure response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Research indicates that the vascular endothelial growth factor (VEGF), or a
      substance made by cells that stimulates new blood vessel formation, plays an important role
      in the growth and metastasis of many cancers, including pancreatic carcinoma. Both VEGF and
      its receptors are overexpressed in pancreatic cancer. Bevacizumab works by blocking VEGF and
      the growth of cancer cells in the process. The current study combines bevacizumab with two
      commonly used pancreatic cancer drugs, gemcitabine and infusional 5-FU. Previous studies
      indicate that bevacizumab combined with other anti-cancer drugs such as 5-FU improves
      patient survival. In addition, other research suggests that the drug administration schedule
      of the current study may improve patient outcomes compared to other types of administration
      and sequencing.

      Purpose: The primary objective of this study is to assess the rate of progression free
      survival at 6 months in patients with advanced pancreatic cancer given gemcitabine,
      infusional 5-FU, and bevacizumab. Secondary objectives of this study include measuring
      response rates, 6 month and 1-year survival rates, and median overall survival.

      Treatment: Study participants will be given bevacizumab, gemcitabine, and 5-FU. These drugs
      will be administered through intravenous infusions in that order every other week on days 1
      and 15. Treatments will be given in 28-day cycles. Participants will therefore receive study
      drugs during weeks 1 and 3, and then receive no study drugs during weeks 2 and 4. Imaging
      exams will be performed every 8 weeks to assess disease size. Several other tests will be
      given throughout the study to closely monitor patients. Tumor level markers will be assessed
      every 4 weeks, but will not be used to measure response. Study treatments will be
      discontinued due to disease growth or severe adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rates Defined by RECIST 1.0</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The National Cancer Institutes Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was used in accessing response for patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 over 100 minutes every 2 weeks.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg every 2 weeks.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusional 5-Fluorouracil</intervention_name>
    <description>2400 mg/m2 over 48 hours every 2 weeks.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Adrucil</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluoroplex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females age &gt;=18 years.

          -  Established histological confirmation of adenocarcinoma of the pancreas.

          -  Stage III and stage IV will be allowed.

        Exclusion Criteria:

          -  No prior chemotherapy or radiotherapy allowed except for that given as part of an
             adjuvant regimen if &gt;4 weeks have elapsed since the end of therapy. Any prior
             treatment with antibodies to VEGF.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to starting the study.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanios Saab, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 15, 2015</lastchanged_date>
  <firstreceived_date>January 2, 2007</firstreceived_date>
  <firstreceived_results_date>May 19, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Tony Bekaii-Saab</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Advanced Pancreatic Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab</title>
          <description>Gemcitabine : 1000 mg/m2 over 100 minutes every 2 weeks.
Bevacizumab : 10 mg/kg every 2 weeks.
Infusional 5-Fluorouracil : 2400 mg/m2 over 48 hours every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non compliance unrelated to toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment -related toxicity</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>42 patients enrolled in study; of which, 39 were evaluable for primary end point.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab</title>
          <description>Gemcitabine : 1000 mg/m2 over 100 minutes every 2 weeks.
Bevacizumab : 10 mg/kg every 2 weeks.
Infusional 5-Fluorouracil : 2400 mg/m2 over 48 hours every 2 weeks.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60" lower_limit="36" upper_limit="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>0 (Fully Active)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>1 (Restricted in physical activity)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Site of metastasis</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Liver only</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Liver+other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other only</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Recurrent metastatic disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Prior adjuvant therapy</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Gemcitabine-based</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Chemoraditation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No prior adjuvant therapy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Disease stage</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>III (Unresectable primary tumor)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>IV (Cancer has spread o distant tissue or organ)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>CA19-9 (tumor marker levels)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Normal (≤37 U/ml)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Elevated (&gt;37 U/ml)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Normal (≥3.4 g/dl)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Low (&lt;3.4 g/dl)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Gemcitabine : 1000 mg/m2 over 100 minutes every 2 weeks.
Bevacizumab : 10 mg/kg every 2 weeks.
Infusional 5-Fluorouracil : 2400 mg/m2 over 48 hours every 2 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy</title>
            <units>percent of patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates Defined by RECIST 1.0</title>
        <description>The National Cancer Institutes Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was used in accessing response for patients</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Gemcitabine: 1000 mg/m2 over 100 minutes every 2 weeks.
Bevacizumab: 10 mg/kg every 2 weeks.
Infusional 5-Fluorouracil: 2400 mg/m2 over 48 hours every 2 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Response Rates Defined by RECIST 1.0</title>
            <description>The National Cancer Institutes Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was used in accessing response for patients</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete Respsonse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Progressive Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were graded according to the NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v 3.0. Toxicity assessments were repeated on day 1 and 15 of every cycle.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab</title>
          <description>Gemcitabine: 1000 mg/m2 over 100 minutes every 2 weeks.
Bevacizumab: 10 mg/kg every 2 weeks.
Infusional 5-Fluorouracil: 2400 mg/m2 over 48 hours every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Fistula formation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Elevated ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Elevated AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered sense of taste</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>42 patients enrolled, 39 were evaluable for the primary end point.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tanios Bekaii-Saab</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-293-9863</phone>
      <email>Tanios.saab@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
